Index - P/E - EPS (ttm) -0.61 Insider Own 18.05% Shs Outstand 51.93M Perf Week -6.02%
Market Cap 244.67M Forward P/E - EPS next Y -0.30 Insider Trans -2.06% Shs Float 42.84M Perf Month 9.35%
Income -30.59M PEG - EPS next Q -0.17 Inst Own 27.36% Short Float 6.60% Perf Quarter 95.00%
Sales 84.04M P/S 2.91 EPS this Y 41.42% Inst Trans 12.28% Short Ratio 1.94 Perf Half Y 188.89%
Book/sh 0.53 P/B 8.81 EPS next Y 44.95% ROA -23.18% Short Interest 2.83M Perf Year 72.69%
Cash/sh 1.25 P/C 3.75 EPS next 5Y - ROE -84.13% 52W Range 1.08 - 6.14 Perf YTD 53.44%
Dividend Est. - P/FCF - EPS past 5Y 18.38% ROI -44.41% 52W High -23.78% Beta 1.80
Dividend TTM - Quick Ratio 2.55 Sales past 5Y 18.67% Gross Margin 91.89% 52W Low 333.33% ATR (14) 0.39
Dividend Ex-Date - Current Ratio 2.94 EPS Y/Y TTM 78.79% Oper. Margin -27.16% RSI (14) 58.00 Volatility 6.55% 8.90%
Employees 100 Debt/Eq 1.70 Sales Y/Y TTM 46.55% Profit Margin -36.40% Recom 1.83 Target Price 8.50
Option/Short Yes / Yes LT Debt/Eq 1.48 EPS Q/Q 63.34% Payout - Rel Volume 0.67 Prev Close 4.69
Sales Surprise -4.83% EPS Surprise -0.96% Sales Q/Q 11.82% Earnings May 01 BMO Avg Volume 1.46M Price 4.68
SMA20 9.50% SMA50 13.05% SMA200 70.46% Trades
Volume 979,510 Change -0.21%
Date
Action
Analyst
Rating Change
Price Target Change
Jan-30-23 Upgrade JP Morgan
Underweight → Neutral
$7 → $10
Jan-03-23 Reiterated Needham
Buy
$32 → $31
Nov-04-21 Downgrade JP Morgan
Neutral → Underweight
$20 → $19
Oct-15-21 Resumed BTIG Research
Buy
$51
Sep-30-21 Downgrade JP Morgan
Overweight → Neutral
$24 → $20
Nov-17-20 Downgrade Raymond James
Strong Buy → Outperform
Jun-26-20 Initiated ROTH Capital
Buy
$55
Jan-21-20 Reiterated H.C. Wainwright
Buy
$72 → $82
Aug-08-19 Upgrade JP Morgan
Neutral → Overweight
Feb-07-19 Initiated B. Riley FBR
Buy
$55
Jan-23-19 Downgrade JP Morgan
Overweight → Neutral
Dec-20-18 Initiated Raymond James
Strong Buy
Nov-08-18 Reiterated Needham
Buy
$76 → $74
Sep-10-18 Resumed BTIG Research
Buy
$80
May-29-18 Initiated H.C. Wainwright
Buy
$61
May-18-18 Reiterated Needham
Buy
$42 → $60
Show Previous Ratings
May-02-24 10:43AM
03:09AM
May-01-24 11:04PM
(Thomson Reuters StreetEvents) +9.55%
05:50PM
09:33AM
07:54AM
Loading…
07:54AM
07:40AM
06:30AM
06:25AM
Apr-17-24 09:00AM
Apr-11-24 09:15AM
Apr-04-24 10:30AM
Apr-01-24 04:20PM
Mar-01-24 04:20PM
Feb-29-24 10:21AM
11:09PM
Loading…
Feb-28-24 11:09PM
(Thomson Reuters StreetEvents) +38.75%
07:40AM
06:51AM
06:30AM
Feb-27-24 08:30AM
Feb-15-24 08:30AM
Feb-13-24 08:15AM
Feb-12-24 04:05PM
Jan-08-24 06:45AM
Jan-03-24 05:02PM
09:00AM
Jan-02-24 04:51PM
Dec-13-23 11:05PM
Dec-05-23 09:26AM
Dec-01-23 04:27PM
08:37PM
Loading…
Nov-29-23 08:37PM
Nov-02-23 09:46AM
Nov-01-23 11:49PM
(Thomson Reuters StreetEvents) -18.79%
09:45AM
06:30AM
Oct-27-23 07:00AM
Oct-26-23 10:02AM
Oct-25-23 10:01AM
Oct-18-23 08:00AM
07:30AM
Oct-16-23 09:00AM
Sep-18-23 07:00AM
Sep-05-23 11:00AM
Sep-01-23 04:15PM
Aug-02-23 07:45AM
06:30AM
Jul-31-23 02:30PM
08:30AM
Jul-27-23 09:42AM
Jul-26-23 09:00AM
Jul-06-23 04:15PM
Jun-04-23 09:17AM
07:13AM
Jun-01-23 04:40PM
May-22-23 04:45PM
May-16-23 07:30AM
May-10-23 07:31AM
May-08-23 06:02AM
May-05-23 06:12AM
May-03-23 02:20PM
(American City Business Journals)
07:45AM
06:30AM
May-01-23 05:00PM
Apr-26-23 12:45PM
Apr-18-23 10:16AM
Apr-12-23 12:00PM
Apr-11-23 12:30PM
Mar-02-23 09:55PM
12:01AM
(Thomson Reuters StreetEvents)
Mar-01-23 07:55AM
06:30AM
Feb-28-23 02:10PM
Feb-22-23 10:00AM
Feb-17-23 07:40AM
Feb-16-23 10:01AM
Feb-15-23 10:00AM
Feb-13-23 01:33PM
(American City Business Journals) -53.16%
08:03AM
07:00AM
06:00AM
Feb-09-23 08:00AM
Feb-01-23 04:46PM
Jan-11-23 07:00AM
Jan-09-23 06:30AM
Jan-04-23 11:01AM
06:30AM
Jan-03-23 02:00PM
Dec-07-22 06:04PM
Dec-01-22 11:41PM
Nov-27-22 10:09PM
(American City Business Journals)
Nov-23-22 10:30AM
Nov-22-22 04:01PM
Nov-17-22 08:12PM
04:01PM
Nov-03-22 08:17AM
Nov-02-22 10:19AM
07:45AM
06:30AM
06:28AM
Nov-01-22 05:40PM
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
Bailey John E. (Jack) Jr. President and CEO May 13 '24 Sale 4.79 37,258 178,421 452,336 May 15 04:06 PM MURDOCK TERRY L Chief Operating Officer May 13 '24 Sale 4.79 8,151 39,034 95,487 May 15 04:10 PM Umstead John W. V Chief Financial Officer May 13 '24 Sale 4.79 8,151 39,034 153,245 May 15 04:11 PM Malik Rajesh Chief Medical Officer May 13 '24 Sale 4.79 8,151 39,034 161,787 May 15 04:08 PM Avagliano Mark Chief Business Officer May 13 '24 Sale 4.79 8,151 39,034 209,683 May 15 04:07 PM Umstead John W. V Chief Financial Officer Mar 18 '24 Sale 3.02 6,547 19,752 123,896 Mar 20 04:32 PM Malik Rajesh Chief Medical Officer Feb 12 '24 Option Exercise 0.30 28,600 8,580 198,538 Feb 13 06:14 PM Malik Rajesh Chief Medical Officer Feb 12 '24 Sale 4.62 28,600 132,143 169,938 Feb 13 06:14 PM MURDOCK TERRY L Chief Operating Officer Jan 04 '24 Sale 2.94 721 2,121 103,638 Jan 08 06:00 AM Avagliano Mark Chief Business Officer Jan 04 '24 Sale 2.94 721 2,121 117,834 Jan 08 06:02 AM Malik Rajesh Chief Medical Officer Jan 04 '24 Sale 2.94 721 2,121 169,938 Jan 08 06:03 AM Umstead John W. V Chief Financial Officer Jan 04 '24 Sale 2.94 111 327 130,443 Jan 08 06:04 AM Bailey John E. (Jack) Jr. President and CEO Jan 03 '24 Sale 3.12 11,686 36,447 489,594 Jan 08 06:02 AM Avagliano Mark Chief Business Officer Jan 03 '24 Sale 3.12 3,360 10,480 118,555 Jan 08 06:02 AM MURDOCK TERRY L Chief Operating Officer Jan 03 '24 Sale 3.12 3,019 9,416 104,359 Jan 08 06:00 AM Malik Rajesh Chief Medical Officer Jan 03 '24 Sale 3.12 3,019 9,416 170,659 Jan 08 06:03 AM Perry Andrew Chief Commercial Officer Jan 03 '24 Sale 3.12 2,413 7,526 87,102 Jan 08 06:03 AM Umstead John W. V Chief Financial Officer Jan 03 '24 Sale 3.12 632 1,971 130,554 Jan 08 06:04 AM Bailey John E. (Jack) Jr. President and CEO Jan 02 '24 Sale 3.27 32,983 108,006 400,580 Jan 02 07:44 PM Malik Rajesh Chief Medical Officer Dec 11 '23 Option Exercise 0.36 33,839 12,081 157,817 Dec 13 04:45 PM Malik Rajesh Chief Medical Officer Dec 11 '23 Sale 3.41 33,839 115,522 136,378 Dec 13 04:45 PM Velleca Mark A. Director Aug 08 '23 Option Exercise 0.39 60,000 23,156 173,286 Aug 10 04:11 PM Velleca Mark A. Director Aug 08 '23 Sale 2.00 60,000 119,974 116,000 Aug 10 04:11 PM Bailey John E. (Jack) Jr. President and CEO Jul 05 '23 Sale 2.45 2,719 6,672 433,563 Jul 07 04:07 PM MURDOCK TERRY L Chief Operating Officer Jul 05 '23 Sale 2.45 1,361 3,339 70,078 Jul 07 04:08 PM Malik Rajesh Chief Medical Officer Jul 05 '23 Sale 2.45 1,361 3,339 136,378 Jul 07 04:08 PM Perry Andrew Chief Commercial Officer Jul 05 '23 Sale 2.45 355 871 55,945 Jul 07 04:08 PM
Index - P/E - EPS (ttm) -0.95 Insider Own 6.36% Shs Outstand 29.09M Perf Week 1.20%
Market Cap 75.60M Forward P/E - EPS next Y -0.65 Insider Trans -10.99% Shs Float 28.09M Perf Month -36.36%
Income -27.54M PEG - EPS next Q -0.27 Inst Own 62.14% Short Float 0.21% Perf Quarter -20.13%
Sales 73.22M P/S 1.03 EPS this Y 11.85% Inst Trans -1.98% Short Ratio 0.32 Perf Half Y 83.94%
Book/sh 0.92 P/B 2.73 EPS next Y 30.04% ROA -26.56% Short Interest 0.06M Perf Year -6.67%
Cash/sh 1.62 P/C 1.56 EPS next 5Y - ROE -72.48% 52W Range 1.03 - 5.07 Perf YTD -13.10%
Dividend Est. - P/FCF - EPS past 5Y 17.12% ROI -30.85% 52W High -50.29% Beta 2.33
Dividend TTM - Quick Ratio 5.18 Sales past 5Y 7.39% Gross Margin 70.12% 52W Low 144.66% ATR (14) 0.31
Dividend Ex-Date - Current Ratio 5.65 EPS Y/Y TTM 29.77% Oper. Margin -37.56% RSI (14) 31.18 Volatility 9.29% 9.90%
Employees 203 Debt/Eq 2.26 Sales Y/Y TTM 10.01% Profit Margin -37.61% Recom 1.00 Target Price 7.00
Option/Short Yes / Yes LT Debt/Eq 2.23 EPS Q/Q 28.83% Payout - Rel Volume 0.76 Prev Close 2.43
Sales Surprise 1.71% EPS Surprise 12.79% Sales Q/Q 12.08% Earnings May 07 BMO Avg Volume 181.97K Price 2.52
SMA20 -22.51% SMA50 -34.76% SMA200 0.16% Trades
Volume 138,415 Change 3.70%
Date
Action
Analyst
Rating Change
Price Target Change
Oct-13-21 Downgrade William Blair
Outperform → Mkt Perform
Oct-13-21 Downgrade BTIG Research
Buy → Neutral
Jan-22-21 Upgrade William Blair
Mkt Perform → Outperform
Feb-06-20 Initiated BTIG Research
Buy
$11
Jul-24-18 Initiated Canaccord Genuity
Buy
May-15-24 07:32AM
May-08-24 09:30AM
03:15AM
May-07-24 11:34PM
(Thomson Reuters StreetEvents) -30.67%
08:58AM
08:40AM
Loading…
08:40AM
07:40AM
(Associated Press Finance)
07:30AM
May-03-24 04:30PM
May-01-24 08:31AM
Apr-23-24 04:30PM
Apr-10-24 08:31AM
Apr-01-24 10:52AM
Mar-27-24 04:30PM
01:10AM
08:30AM
Loading…
Mar-25-24 08:30AM
Mar-08-24 08:06AM
Mar-07-24 02:00PM
10:16AM
08:22AM
Mar-05-24 11:39PM
(Thomson Reuters StreetEvents) +15.41%
08:40AM
07:46AM
(Associated Press Finance)
07:30AM
Feb-20-24 08:30AM
Feb-12-24 08:32AM
Feb-06-24 08:28AM
Jan-08-24 08:30AM
Dec-18-23 08:49AM
Dec-04-23 08:56AM
04:15PM
Loading…
Nov-15-23 04:15PM
Nov-13-23 08:57AM
Nov-09-23 08:32AM
Nov-08-23 01:16PM
Nov-07-23 07:57AM
07:43AM
(Associated Press Finance)
07:30AM
Nov-06-23 04:30PM
Oct-24-23 08:30AM
Oct-16-23 08:56AM
Oct-03-23 09:21AM
Sep-12-23 08:56AM
Aug-21-23 08:56AM
Aug-18-23 09:02PM
Aug-14-23 09:02AM
Aug-11-23 12:00PM
Aug-08-23 08:22AM
(Associated Press Finance)
07:30AM
Aug-04-23 04:30PM
Jul-25-23 08:30AM
Jul-19-23 08:56AM
Jul-17-23 08:46AM
Jul-11-23 08:56AM
Jun-12-23 11:25AM
11:18AM
08:59AM
Jun-09-23 09:50AM
08:53AM
Jun-08-23 12:18PM
09:31AM
Jun-06-23 11:19AM
08:04AM
Jun-02-23 10:26AM
08:33AM
Jun-01-23 08:39AM
May-31-23 09:16AM
May-30-23 01:50PM
May-29-23 02:06AM
May-26-23 08:59AM
May-25-23 12:25PM
May-24-23 04:30PM
09:34AM
May-23-23 10:10AM
08:46AM
May-22-23 08:01AM
May-18-23 10:16AM
May-17-23 11:09AM
May-15-23 08:56AM
07:58AM
May-09-23 05:00PM
08:55AM
07:30AM
May-08-23 08:47AM
May-05-23 08:30AM
May-03-23 08:58AM
May-02-23 09:01AM
May-01-23 08:46AM
Apr-28-23 04:11PM
Apr-25-23 08:30AM
Apr-18-23 02:14PM
Apr-13-23 08:58AM
Apr-06-23 04:16PM
Apr-04-23 08:30AM
Mar-16-23 08:56AM
Mar-08-23 10:02PM
12:44AM
(Thomson Reuters StreetEvents)
Mar-07-23 08:45AM
07:30AM
Mar-02-23 04:02PM
Feb-27-23 04:30PM
Neuronetics, Inc. is a commercial stage medical technology company, which focuses on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders. It operates through United States and International geographical segments. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon, and Thomas D. Weldon in 1998 and is headquartered in Malvern, PA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
MACAN WILLIAM ANDREW EVP, GC, CCO and CS Feb 29 '24 Sale 2.94 6,026 17,716 389,333 Mar 01 05:02 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Feb 28 '24 Sale 3.16 22,377 70,711 395,359 Mar 01 05:02 PM Furlong Stephen EVP, CFO and Treasurer Feb 28 '24 Sale 3.16 3,985 12,593 483,776 Feb 29 05:02 PM Furlong Stephen EVP, CFO and Treasurer Feb 27 '24 Sale 3.33 21,272 70,836 487,761 Feb 29 05:02 PM Sullivan Keith J President and CEO Feb 26 '24 Sale 3.30 20,292 66,964 1,372,278 Feb 28 05:02 PM Sullivan Keith J President and CEO Feb 23 '24 Sale 3.23 20,750 67,022 1,392,570 Feb 26 05:21 PM Sullivan Keith J President and CEO Feb 22 '24 Sale 3.23 20,851 67,349 1,413,320 Feb 26 05:21 PM Sullivan Keith J President and CEO Feb 20 '24 Sale 2.96 23,958 70,916 1,434,171 Feb 22 05:02 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Feb 14 '24 Sale 3.38 15,621 52,799 417,736 Feb 16 05:11 PM Furlong Stephen EVP, CFO and Treasurer Feb 09 '24 Sale 3.51 14,710 51,632 509,033 Feb 13 06:00 PM Furlong Stephen EVP, CFO and Treasurer Feb 06 '24 Sale 3.39 5,813 19,706 523,743 Feb 07 05:41 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Feb 06 '24 Sale 3.39 5,385 18,255 433,357 Feb 07 05:42 PM Sullivan Keith J President and CEO Jan 11 '24 Sale 3.16 9,516 30,071 1,158,129 Jan 12 06:00 PM Sullivan Keith J President and CEO Jan 10 '24 Sale 3.01 10,013 30,139 1,167,645 Jan 12 06:00 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Dec 21 '23 Sale 2.52 11,663 29,391 348,742 Dec 21 07:42 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Dec 20 '23 Sale 2.70 11,664 31,493 360,405 Dec 21 07:42 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Dec 19 '23 Sale 2.24 11,664 26,127 372,069 Dec 21 07:42 PM Furlong Stephen EVP, CFO and Treasurer Oct 06 '23 Sale 1.16 1,499 1,731 429,556 Oct 10 05:10 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Oct 06 '23 Sale 1.16 1,469 1,697 383,733 Oct 10 05:12 PM Sullivan Keith J President and CEO Jul 21 '23 Sale 2.04 6,551 13,364 1,177,658 Jul 25 07:50 PM Sullivan Keith J President and CEO Jul 20 '23 Sale 2.06 6,510 13,411 1,184,209 Jul 21 06:15 PM Sullivan Keith J President and CEO Jul 19 '23 Sale 2.07 6,479 13,412 1,190,719 Jul 21 06:15 PM MACAN WILLIAM ANDREW EVP, GC, CCO and CS Jul 11 '23 Sale 2.13 2,645 5,634 385,202 Jul 12 08:35 PM BAKEWELL JOHN K Director May 24 '23 Sale 2.70 14,400 38,880 77,988 May 26 04:10 PM
Index - P/E 677.61 EPS (ttm) 0.25 Insider Own 7.03% Shs Outstand 55.77M Perf Week 3.72%
Market Cap 9.56B Forward P/E 85.13 EPS next Y 2.01 Insider Trans -0.65% Shs Float 51.95M Perf Month 6.24%
Income 14.84M PEG 39.60 EPS next Q 0.33 Inst Own 101.42% Short Float 8.50% Perf Quarter -16.99%
Sales 607.45M P/S 15.73 EPS this Y -16.94% Inst Trans 1.47% Short Ratio 8.99 Perf Half Y 11.21%
Book/sh 35.29 P/B 4.85 EPS next Y 38.21% ROA 0.55% Short Interest 4.42M Perf Year 12.63%
Cash/sh 13.97 P/C 12.24 EPS next 5Y 17.11% ROE 0.76% 52W Range 110.45 - 211.13 Perf YTD -4.88%
Dividend Est. - P/FCF 87.25 EPS past 5Y 15.08% ROI 0.56% 52W High -18.99% Beta 1.07
Dividend TTM - Quick Ratio 5.24 Sales past 5Y 31.42% Gross Margin 42.41% 52W Low 54.85% ATR (14) 5.98
Dividend Ex-Date - Current Ratio 6.35 EPS Y/Y TTM -91.17% Oper. Margin 5.52% RSI (14) 51.46 Volatility 3.44% 3.58%
Employees 1783 Debt/Eq 0.37 Sales Y/Y TTM -21.90% Profit Margin 2.44% Recom 1.50 Target Price 204.80
Option/Short Yes / Yes LT Debt/Eq 0.33 EPS Q/Q -92.68% Payout 0.00% Rel Volume 0.88 Prev Close 176.03
Sales Surprise -3.30% EPS Surprise -6.98% Sales Q/Q -17.14% Earnings May 01 BMO Avg Volume 491.32K Price 171.03
SMA20 3.34% SMA50 -3.30% SMA200 0.19% Trades
Volume 430,952 Change -2.84%
Date
Action
Analyst
Rating Change
Price Target Change
Dec-04-23 Downgrade The Benchmark Company
Buy → Hold
Jul-20-23 Initiated Wells Fargo
Overweight
$185
Jul-05-23 Resumed JP Morgan
Overweight
$220
Mar-28-23 Initiated The Benchmark Company
Buy
$230
Dec-14-22 Initiated Deutsche Bank
Hold
$180
Dec-07-22 Initiated RBC Capital Mkts
Sector Perform
$190
Jul-20-22 Initiated UBS
Buy
$213
Oct-14-21 Initiated Exane BNP Paribas
Outperform
$330
Nov-10-20 Initiated KeyBanc Capital Markets
Overweight
$241
Aug-24-20 Reiterated H.C. Wainwright
Buy
$151 → $168
Jun-30-20 Reiterated H.C. Wainwright
Buy
$143 → $151
May-07-20 Reiterated H.C. Wainwright
Buy
$100 → $143
Mar-23-20 Reiterated H.C. Wainwright
Buy
$110 → $100
Nov-15-19 Initiated Stifel
Buy
Nov-01-19 Upgrade First Analysis Sec
Outperform → Strong Buy
$107 → $110
Oct-15-19 Initiated SVB Leerink
Outperform
$100
Aug-28-19 Reiterated First Analysis Sec
Outperform
$95 → $107
Aug-23-19 Resumed Stephens
Overweight
Jul-22-19 Upgrade H.C. Wainwright
Neutral → Buy
$110
Dec-17-18 Upgrade CL King
Neutral → Buy
Show Previous Ratings
May-15-24 09:53AM
May-07-24 07:30AM
May-02-24 11:31AM
11:31AM
11:23AM
03:06AM
Loading…
03:06AM
May-01-24 11:53AM
09:11AM
08:50AM
08:47AM
07:47AM
(Associated Press Finance)
07:30AM
Apr-23-24 11:43AM
Apr-17-24 07:30AM
Apr-12-24 10:07AM
09:49AM
Loading…
09:49AM
Mar-19-24 07:30AM
Mar-12-24 01:18AM
Feb-27-24 02:02AM
Feb-24-24 12:03AM
Feb-22-24 11:24AM
10:39AM
Feb-21-24 08:45AM
08:12AM
07:51AM
(Associated Press Finance)
07:30AM
Feb-07-24 07:30AM
Jan-31-24 12:10PM
Jan-29-24 05:09AM
Dec-19-23 07:30AM
04:49AM
Loading…
Dec-18-23 04:49AM
Dec-07-23 07:30AM
Nov-30-23 11:31AM
Nov-15-23 07:15AM
Nov-14-23 02:01PM
07:30AM
Nov-07-23 07:30AM
Nov-02-23 07:30AM
Nov-01-23 12:10PM
11:46AM
12:04AM
(Thomson Reuters StreetEvents)
Oct-31-23 09:41AM
09:12AM
08:50AM
07:41AM
(Associated Press Finance)
07:30AM
Oct-25-23 10:01AM
Oct-24-23 10:00AM
Oct-17-23 11:44AM
07:30AM
Oct-02-23 07:30AM
Sep-27-23 06:51AM
Sep-26-23 12:41PM
(American City Business Journals)
07:30AM
Sep-14-23 10:10AM
Sep-12-23 07:30AM
Sep-06-23 03:06AM
Sep-01-23 12:19PM
11:31AM
07:30AM
Aug-21-23 06:53AM
Aug-17-23 08:00AM
Aug-10-23 09:39AM
Aug-09-23 06:10AM
Aug-03-23 11:19AM
Aug-02-23 08:55AM
07:49AM
07:30AM
Jul-31-23 09:08AM
Jul-26-23 10:02AM
Jul-25-23 11:40AM
Jul-20-23 10:01AM
Jul-19-23 07:30AM
Jul-10-23 08:34AM
Jun-30-23 10:54AM
Jun-21-23 08:00PM
Jun-07-23 11:30AM
Jun-02-23 11:31AM
Jun-01-23 11:31AM
May-31-23 07:30AM
May-30-23 12:09PM
May-09-23 05:52PM
May-03-23 01:20PM
May-02-23 11:36PM
(Thomson Reuters StreetEvents)
08:55AM
07:52AM
07:30AM
07:02AM
May-01-23 07:43AM
Apr-26-23 08:00PM
10:02AM
Apr-25-23 02:07PM
10:01AM
Apr-18-23 07:30AM
Apr-11-23 02:41PM
Mar-24-23 11:30AM
Mar-14-23 07:30AM
Feb-23-23 06:28PM
01:41PM
05:54AM
Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.
Insider Trading
Relationship
Date
Transaction
Cost
#Shares
Value ($)
#Shares Total
SEC Form 4
KURIYEL RALF Senior VP, R&D Mar 11 '24 Option Exercise 86.10 1,271 109,433 27,777 Mar 12 08:24 PM KURIYEL RALF Senior VP, R&D Mar 11 '24 Sale 193.73 3,517 681,348 24,260 Mar 12 08:24 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Option Exercise 16.55 1 17 201,956 Mar 11 07:43 PM Hunt Anthony Chief Executive Officer Mar 08 '24 Sale 197.44 16,707 3,298,632 185,249 Mar 11 07:43 PM DAWES KAREN A Director Feb 27 '24 Option Exercise 42.07 4,626 194,616 88,367 Feb 28 09:56 PM DAWES KAREN A Director Feb 27 '24 Sale 193.35 1,000 193,350 87,367 Feb 28 09:56 PM Bylund James Chief Operating Officer Feb 23 '24 Option Exercise 94.33 940 88,670 18,508 Feb 26 08:38 PM Bylund James Chief Operating Officer Feb 23 '24 Sale 198.08 4,373 866,204 14,135 Feb 26 08:38 PM Gebski Christine See Remarks Nov 10 '23 Sale 147.13 3,788 557,328 28,787 Nov 13 05:10 PM DAWES KAREN A Director Aug 29 '23 Option Exercise 18.12 7,392 133,943 84,591 Aug 30 04:06 PM DAWES KAREN A Director Aug 29 '23 Sale 171.38 850 145,673 83,741 Aug 30 04:06 PM
×
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features.
Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite
